|
|
|
| Relationship between the expression of long non-coding RNA OSTN-AS1 and microRNA-1207-3p in prostate cancer tissues and clinicopathological parameters and prognosis |
| LI Xuyu ZHANG Yu ZHANG Haijian HAN Zhixing JI Shiqi LIU Qingjun |
| Department of Urology Surgery, Beijing Ditan Hospital Capital Medical University, Beijing 100015, China |
|
|
|
|
Abstract Objective To investigate the expression of long non-coding RNA (lncRNA) OSTN-AS1 and microrNA (miR) - 1207-3p in prostate cancer (PCa) tissues and their relationship with clinicopathological parameters and prognosis. Methods A total of 102 PCa patients admitted to Beijing Ditan Hospital Capital Medical University from January 2015 to December 2017 were selected. Real-time fluorescence quantitative PCR was used to detect the expression of lncRNA OSTN-AS1 and miR-1207-3p in cancer tissues and adjacent tissues, and the relationship between the expression and clinicopathological characteristics was analyzed. According to the mean expression of lncRNA OSTN-AS1 and miR-1207-3p in cancer tissues, patients were divided into low lncRNA OSTN-AS1 expression group (＜3.26, 50 cases) and high lncRNA OSTN-AS1 expression group (≥3.26, 52 cases); and low miR-1207-3p expression group (＜3.69, 49 cases) and high miR-1207-3p expression group (≥3.69, 53 cases). Follow-up for five years was conducted to analyze the relationship between lncRNA OSTN-AS1, miR-1207-3p, and prognosis. Cox regression analysis of the factors affecting the prognosis of PCa patients. Results The expressions of lncRNA OSTN-AS1 and miR- 1207-3p in PCa tissues were higher than those in paracancer tissues, and the differences were statistically significant (P＜0.05). The expression levels of lncRNA OSTN-AS1 and miR-1207-3p in PCa tissues with different TNM stages, Gleason score and lymph node metastasis were statistically significant (P＜0.05). The 5-year cumulative survival rate of lncRNA OSTN-AS1 high expression group was lower than that of lncRNA OSTN-AS1 low expression group (P＜0.05). The 5-year cumulative survival rate of miR-1207-3p high expression group was lower than that of miR-1207-3p low expression group (P＜0.05). Cox regression analysis showed that TNM stage Ⅲ, Gleason score ＞ seven points, lymph node metastasis, lncRNA OSTN-AS1 high expression, and miR-1207-3p high expression were independent risk factors for the prognosis of PCa patients (P＜0.05). Conclusion The expression of lncRNA OSTN-AS1 and miR-1207-3p increased in PCa tissues, which were related to Gleason score, TNM stage, lymph node metastasis, and prognosis survival, and involved in tumor progression in PCa.
|
|
|
|
|
|
[1] Rebello RJ，Oing C，Knudsen KE，et al. Prostate cancer [J]. Nat Rev Dis Primers，2021，7（1）：8-15.
[2] 张烨，王磊，张璐，等.雄激素受体剪接变异体7在去势抵抗性前列腺癌中的作用及其临床意义[J].中国医药导报，2020，17（1）：46-49.
[3] Yan H，Bu P. Non-coding RNA in cancer [J]. Essays Biochem，2021，65（4）：625-639.
[4] Liu Z，Mi M，Li X，et al. lncRNA OSTN-AS1 May Represent a Novel Immune-Related Prognostic Marker for Triple-Negative Breast Cancer Based on Integrated Analysis of a ceRNA Network [J]. Front Genet，2019，10（7）：850-859.
[5] Wang X，Li L，Xiao W，et al. Plasma microRNA-1207-5p as a Potential Biomarker for Diagnosis and Prognosis of Colorectal Cancer [J]. Clin Lab，2020，66（9）：236-241.
[6] Zhang Q，Zheng J，Liu L. Down-regulation of lncRNA LUADT1 suppresses cervical cancer cell growth by sequestering microRNA-1207-5p [J]. Acta Biochim Biophys Sin （Shanghai），2022，54（3）：321-331.
[7] 李星，曾晓勇.中国前列腺癌流行病学研究进展[J].肿瘤防治研究，2021，48（1）：98-102.
[8] 彭妙官，张莹.前列腺癌低氧相关基因预后风险模型的建立与分析[J].热带医学杂志，2022，22（4）：544-548.
[9] 温健男，程超，章泽宇，等.血清前列腺特异性抗原联合Gleason评分对初诊前列腺癌转移风险的预测价值[J].第二军医大学学报，2021，42（4）：371-376.
[10] 李娜，左树森，乔玉华.血清PSA、TGF-β1、uPAR、AMACR和尿肌氨酸在前列腺癌诊断中的效能分析[J].山东医药，2023，63（5）：71-74.
[11] Wen S，Wei Y，Zen C，et al. Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6- methyladenosine [J]. Mol Cancer，2020，19（1）：171-179.
[12] Mugoni V，Ciani Y，Nardella C，et al. Circulating RNAs in prostate cancer patients [J]. Cancer Lett，2022，524（7）：57-69.
[13] Ding L，Wang R，Shen D，et al. Role of noncoding RNA in drug resistance of prostate cancer [J]. Cell Death Dis，2021， 12（6）：590-599.
[14] 田莉，赵济华，徐晋珩，等.lncRNA OSTN-AS1下调miR- 4461表达促进前列腺癌LNCaP细胞增殖、迁移和侵袭[J].医学分子生物学杂志，2023，20（3）：215-220.
[15] 崔海军，田莉，赵济华，等.lncRNA OSTN-AS1通过靶向调控miR-330-5p表达对前列腺癌DU145细胞增殖、迁移及侵袭的影响[J].中国男科学杂志，2022，36（4）：62-67.
[16] Jiang T，Guo J，Hu Z，et al. Identification of Potential Prostate Cancer-Related Pseudogenes Based on Competitive Endogenous RNA Network Hypothesis [J]. Med Sci Monit，2018， 24（9）：4213-4239.
[17] Zang Y，Zhu J，Li Q，et al. miR-137-3p Modulates the Progression of Prostate Cancer by Regulating the JNK3/ EZH2 Axis [J]. Onco Targets Ther，2020，13（5）：7921-7932.
[18] Diener C，Keller A，Meese E. Emerging concepts of miRNA therapeutics：from cells to clinic [J]. Trends Genet，2022，38（6）：613-626.
[19] Coradduzza D，Cruciani S，Arru C，et al. Role of miRNA- 145，148，and 185 and Stem Cells in Prostate Cancer [J]. Int J Mol Sci，2022，23（3）：1626.
[20] Chakraborty S，Nath D. A Study on microRNAs Targeting the Genes Overexpressed in Lung Cancer and their Codon Usage Patterns [J]. Mol Biotechnol，2022，64（10）：1095-1119.
[21] Liu X，Zeng Y，Liu Z，et al. Bioinformatics analysis of the circRNA-miRNA-mRNA network for atrial fibrillation [J]. Medicine （Baltimore），2022，101（34）：e30221.
[22] Das DK，Osborne JR，Lin HY，et al. miR-1207-3p Is a Novel Prognostic Biomarker of Prostate Cancer [J]. Transl Oncol，2016，9（3）：236-241.
[23] Das DK，Naidoo M，Ilboudo A，et al. miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin [J]. Exp Cell Res，2016，348（2）：190-200.
[24] Bi Y，Ji J，Zhou Y. LncRNA-PVT1 indicates a poor prognosis and promotes angiogenesis via activating the HNF1B/ EMT axis in glioma [J]. J Cancer，2021，12（19）：5732-5744.
[25] You L，Wang H，Yang G，et al. Gemcitabine exhibits a suppressive effect on pancreatic cancer cell growth by regulating processing of PVT1 to miR1207 [J]. Mol Oncol，2018， 12（12）：2147-2164. |
|
|
|
